DOCSLIB.ORG

(21) International Application Number

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(21) International Application Number ( (51) International Patent Classification: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, C12N 15/86 (2006.0 1) A61K 9/51 (2006.0 1) MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, C07K 14/705 (2006.01) TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2020/049087 Declarations under Rule 4.17: (22) International Filing Date: — as to the applicant's entitlement to claim the priority of the 02 September 2020 (02.09.2020) earlier application (Rule 4.17(iii)) — of inventorship (Rule 4.17(iv)) (25) Filing Language: English Published: (26) Publication Language: English — with international search report (Art. 21(3)) (30) Priority Data: — with sequence listing part of description (Rule 5.2(a)) 62/895,454 03 September 2019 (03.09.2019) US 63/056,5 14 24 July 2020 (24.07.2020) US (71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US]; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). (72) Inventors: EMMANUEL, Akinola Olumide; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). ENNAJDAOUI, Hanane; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). JAIN, Suvi; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). RUZO MATIAS, Alberto; 188 East Blaine Street, Suite 400, Seattle, Washington 98 102 (US). SHAH, Jagesh V.; 188 East Blaine Street, Suite 400, Seattle, Washington 98102 (US). (74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP, 1253 1 High Bluff Drive, Suite 100, San Diego, California 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: CD24-ASSOCIATED PARTICLES AND RELATED METHODS AND USES THEREOF (57) Abstract: Provided herein are non-cell particles, e.g. virus particles or virus-like particles, such as pseudotyped lentiviral-like particles, containing an exogenous CD24 or a biologically active portion of CD24. In some embodiments, the non-cell particles, e.g. virus particles or virus-like particles, such as pseudotyped lentiviral-like particles, can further contain an exogenous CD47 or a biolog¬ ically active portion of CD47. Also provided herein are compositions containing such non-cell particles and methods of making and using the non-cell particles. CD24-ASSOCIATED PARTICLES AND RELATED METHODS AND USES THEREOF Cross-Reference to Related Applications [0001] This application claims priority to U.S. provisional application 62/895,454, filed September 3, 2020, and to U.S. provisional application 63/056,514, filed July 24, 2020, the contents of each of which are incorporated by reference in their entirety for all purposes. Incorporation by Reference of Sequence Listing [0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled 186152003740SeqList.TXT, created September 2, 2020, which is 202,892 bytes in size. The information in the electronic format of the Sequence Listing is incorporated by reference in its entirety. Field [0003] The present disclosure relates to non-cell particles, e.g. vims particles or vims-like particles, such as pseudotyped lentiviral-like particles, containing an exogenous CD24 or a biologically active portion of CD24. In some embodiments, the non-cell particles, e.g. vims particles or virus-like particles, such as pseudotyped lentiviral-like particles, can further contain an exogenous CD47 or a biologically active portion of CD47. The present disclosure also provides compositions containing such non-cell particles and methods of making and using the non-cell particles. Background [0004] Non-cell particles, such as lentiviral-like vector particles, are commonly used in gene therapy for delivery of exogenous agents to cells. When administered to subjects, however, such particles can be recognized as foreign and can be engulfed or scavenged by phagocytic cells. Phagocytosis is conducted primarily by highly specialized cells, such as macrophages, monocytes and neutrophils, with the goal of clearing pathogens and/or other foreign invaders that the phagocytic cell recognizes through an array of specialized pattern recognition receptors. Phagocytosis of particles, such as lentiviral vector particles, limits the in vivo half-life and their effectiveness as gene therapy vectors. Thus, there is a long felt need for effective particle delivery vehicles, including lentiviral-like particles along with other types of non-cell particles, for effectively evading the phagocytic cell uptake of the immune system, thereby resulting in a reduction of an immune response. The provided disclosure addresses this need. Summary [0005] Provided herein is a non-cell particle comprising CD24 or a biologically active portion thereof on an exposed surface of the particle, wherein the non-cell particle is 1 pm or smaller. In some embodiments, the CD24 or the biologically active portion thereof binds Siglec- 10. In some embodiments, the CD24 or biologically active portion thereof is human. [0006] In some embodiments, the CD24 or biologically active portion thereof (i) comprises the sequence set forth in SEQ ID NO: 2; (ii) an amino acid sequence having at least at or about 90%, at least at or about 91 , at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:2 that binds Siglec- 10; or (iii) a binding portion of (i) or (ii) that binds to Siglec-10. In some embodiments, the CD24 or biologically active portion thereof comprises the sequence set forth in SEQ ID NO:2. [0007] In some embodiments, the CD24 or biologically active portion is displayed on an exposed surface of the particle via a Glycosylphosphatidylinositol (GPI) membrane anchor. [0008] In some embodiments, the CD24 or the biologically active portion thereof is encoded by a nucleic molecule encoding the sequence set forth in SEQ ID NOG or an amino acid sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NOG that binds Siglec-10. In some embodiments, the CD24 or the biologically active portion thereof is encoded by a nucleic molecule encoding the sequence set forth in SEQ ID NO: 15 or an amino acid sequence having at least at or about 90%, at least at or about 91%, at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO: 15 that binds Siglec-10. [0009] In some embodiments, the CD24 or biologically active portion is displayed on an exposed surface of the particle via a transmembrane domain. [0010] In some embodiments, the CD24 or biologically active portion is a glycoprotein. In some embodiments, the CD24 or biologically active portion is sialylated. In some embodiments, the CD24 or biologically active portion comprises an a2-3-linked sialoside and/or an a2-6- linked sialoside. In some embodiments, the CD24 or biologically active portion has a molecular weight of between at or about 35 kDa and at or about 45 kDa. [0011] In some embodiments, the non-cell particle further comprises a CD47 or a biologically active portion thereof on an exposed surface of the non-cell particle. In some embodiments, the CD47 or biologically active portion binds to SIRPa. In some embodiments, the CD47 or biologically active portion is human. In some embodiments, the CD47 or biologically active portion comprises the extracellular domain or CD47 or a binding portion thereof that binds to SIRPa. [0012] In some embodiments, the CD47 or biologically active portion thereof (i) comprises the sequence set forth in SEQ ID NO: 7; (ii) an amino acid sequence having at least at or about 90%, at least at or about 91 , at least at or about 92%, at least at or about 93%, at least at or about 94%, at least at or about 95%, at least at or about 96%, at least at or about 97%, at least at or about 98%, or at least at or about 99% sequence identity to SEQ ID NO:7 that binds to SIRPa; or (iii) a binding portion of (i) or (ii) that binds to SIRPa.
Load more

Recommended publications
  • Replication by Iga Intraepithelial Cell Neutralization of HIV-1
    Intraepithelial Cell Neutralization of HIV-1 Replication by IgA Yung T. Huang, Alison Wright, Xing Gao, Lesya Kulick, Huimin Yan and Michael E. Lamm This information is current as of October 1, 2021. J Immunol 2005; 174:4828-4835; ; doi: 10.4049/jimmunol.174.8.4828 http://www.jimmunol.org/content/174/8/4828 Downloaded from References This article cites 57 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/174/8/4828.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2005 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Intraepithelial Cell Neutralization of HIV-1 Replication by IgA1 Yung T. Huang,2*† Alison Wright,* Xing Gao,* Lesya Kulick,* Huimin Yan,3* and Michael E. Lamm* HIV is transmitted sexually through mucosal surfaces where IgA Abs are the first line of immune defense.
    [Show full text]
  • Characterization of the Relationship Between Measles Virus Fusion
    University of Massachusetts Medical School eScholarship@UMMS GSBS Dissertations and Theses Graduate School of Biomedical Sciences 2006-05-17 Characterization of the Relationship Between Measles Virus Fusion, Receptor Binding, and the Virus-Specific Interaction Between the Hemagglutinin and Fusion Glycoproteins: a Dissertation Elizabeth Ann Corey University of Massachusetts Medical School Let us know how access to this document benefits ou.y Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss Part of the Amino Acids, Peptides, and Proteins Commons, Cells Commons, Chemical Actions and Uses Commons, Lipids Commons, and the Virus Diseases Commons Repository Citation Corey EA. (2006). Characterization of the Relationship Between Measles Virus Fusion, Receptor Binding, and the Virus-Specific Interaction Between the Hemagglutinin and Fusion Glycoproteins: a Dissertation. GSBS Dissertations and Theses. https://doi.org/10.13028/hg2y-0r35. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/221 This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and Theses by an authorized administrator of eScholarship@UMMS. For more information, please contact [email protected]. CHARACTERIZATION OF THE RELATIONSHIP BETWEEN MEASLES VIRUS FUSION , RECEPTOR BINDING , AND THE VIRUS-SPECIFIC INTERACTION BETWEEN THE HEMAGGLUTININ AND FUSION GL YCOPROTEINS A Dissertation Presented Elizabeth Anne Corey Submitted to the Faculty of the University of Massachusetts Graduate
    [Show full text]
  • The Accessory Glycoprotein Gp3 of Canine Coronavirus Type 1
    The accessory glycoprotein gp3 of canine Coronavirus type 1 : investigations of sequence variability in feline host and of the basic features of the different variants Anne-Laure Pham-Hung d’Alexandry d’Orengiani To cite this version: Anne-Laure Pham-Hung d’Alexandry d’Orengiani. The accessory glycoprotein gp3 of canine Coro- navirus type 1 : investigations of sequence variability in feline host and of the basic features of the different variants. Virology. Université Paris Sud - Paris XI, 2014. English. NNT : 2014PA114831. tel-01089374 HAL Id: tel-01089374 https://tel.archives-ouvertes.fr/tel-01089374 Submitted on 1 Dec 2014 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITÉ PARIS-SUD 11 ECOLE DOCTORALE : INNOVATION THÉRAPEUTIQUE : DU FONDAMENTAL A L’APPLIQUÉ PÔLE : MICROBIOLOGIE / THERAPEUTIQUES ANTIINFECTIEUSES DISCIPLINE : VIROLOGIE ANNÉE 2013 - 2014 SÉRIE DOCTORAT N° 1296 THÈSE DE DOCTORAT soutenue le 24/10/2014 par Anne-Laure Pham-Hung d’Alexandry d’Orengiani The accessory glycoprotein gp3 of canine Coronavirus type 1 : investigations
    [Show full text]
  • APICAL M2 PROTEIN IS REQUIRED for EFFICIENT INFLUENZA a VIRUS REPLICATION by Nicholas Wohlgemuth a Dissertation Submitted To
    APICAL M2 PROTEIN IS REQUIRED FOR EFFICIENT INFLUENZA A VIRUS REPLICATION by Nicholas Wohlgemuth A dissertation submitted to Johns Hopkins University in conformity with the requirements for the degree of Doctor of Philosophy Baltimore, Maryland October, 2017 © Nicholas Wohlgemuth 2017 All rights reserved ABSTRACT Influenza virus infections are a major public health burden around the world. This dissertation examines the influenza A virus M2 protein and how it can contribute to a better understanding of influenza virus biology and improve vaccination strategies. M2 is a member of the viroporin class of virus proteins characterized by their predicted ion channel activity. While traditionally studied only for their ion channel activities, viroporins frequently contain long cytoplasmic tails that play important roles in virus replication and disruption of cellular function. The currently licensed live, attenuated influenza vaccine (LAIV) contains a mutation in the M segment coding sequence of the backbone virus which confers a missense mutation (alanine to serine) in the M2 gene at amino acid position 86. Previously discounted for not showing a phenotype in immortalized cell lines, this mutation contributes to both the attenuation and temperature sensitivity phenotypes of LAIV in primary human nasal epithelial cells. Furthermore, viruses encoding serine at M2 position 86 induced greater IFN-λ responses at early times post infection. Reversing mutations such as this, and otherwise altering LAIV’s ability to replicate in vivo, could result in an improved LAIV development strategy. Influenza viruses infect at and egress from the apical plasma membrane of airway epithelial cells. Accordingly, the virus transmembrane proteins, HA, NA, and M2, are all targeted to the apical plasma membrane ii and contribute to egress.
    [Show full text]
  • The Nucleoprotein and Phosphoprotein of Peste Des Petits Ruminants Virus Inhibit Interferons Signaling by Blocking the JAK-STAT Pathway
    viruses Article The Nucleoprotein and Phosphoprotein of Peste des Petits Ruminants Virus Inhibit Interferons Signaling by Blocking the JAK-STAT Pathway 1,2, 2, 2 2 2 2 Pengfei Li y , Zixiang Zhu y, Xiangle Zhang , Wen Dang , Linlin Li , Xiaoli Du , Miaotao Zhang 1, Chunyan Wu 1, Qinghong Xue 3, Xiangtao Liu 2, Haixue Zheng 2,* and Yuchen Nan 1,* 1 Department of Preventive Veterinary Medicine, College of Veterinary Medicine, Northwest A&F University, Yangling 712100, China 2 State Key Laboratory of Veterinary Etiological Biology, National Foot and Mouth Diseases Reference Laboratory, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China 3 China Institute of Veterinary Drug Control, Beijing100081, China * Correspondence: [email protected] (H.Z.); [email protected] (Y.N.) These authors contributed equally to this work. y Received: 17 June 2019; Accepted: 6 July 2019; Published: 8 July 2019 Abstract: Peste des petits ruminants virus (PPRV) is associated with global peste des petits ruminants resulting in severe economic loss. Peste des petits ruminants virus dampens host interferon-based signaling pathways through multiple mechanisms. Previous studies deciphered the role of V and C in abrogating IFN-β production. Moreover, V protein directly interacted with signal transducers and activators of transcription 1 (STAT1) and STAT2 resulting in the impairment of host IFN responses. In our present study, PPRV infection inhibited both IFN-β- and IFN-γ-induced activation of IFN-stimulated response element (ISRE) and IFN-γ-activated site (GAS) element, respectively. Both N and P proteins, functioning as novel IFN response antagonists, markedly suppressed IFN-β-induced ISRE and IFN-γ-induced GAS promoter activation to impair downstream upregulation of various interferon-stimulated genes (ISGs) and prevent STAT1 nuclear translocation.
    [Show full text]
  • Impact of RNA Virus Evolution on Quasispecies Formation and Virulence
    International Journal of Molecular Sciences Review Impact of RNA Virus Evolution on Quasispecies Formation and Virulence Madiiha Bibi Mandary, Malihe Masomian and Chit Laa Poh * Center for Virus and Vaccine Research, School of Science and Technology, Sunway University, Kuala Lumpur, Selangor 47500, Malaysia * Correspondence: [email protected]; Tel.: +60-3-7491-8622; Fax: +60-3-5635-8633 Received: 3 July 2019; Accepted: 26 August 2019; Published: 19 September 2019 Abstract: RNA viruses are known to replicate by low fidelity polymerases and have high mutation rates whereby the resulting virus population tends to exist as a distribution of mutants. In this review, we aim to explore how genetic events such as spontaneous mutations could alter the genomic organization of RNA viruses in such a way that they impact virus replications and plaque morphology. The phenomenon of quasispecies within a viral population is also discussed to reflect virulence and its implications for RNA viruses. An understanding of how such events occur will provide further evidence about whether there are molecular determinants for plaque morphology of RNA viruses or whether different plaque phenotypes arise due to the presence of quasispecies within a population. Ultimately this review gives an insight into whether the intrinsically high error rates due to the low fidelity of RNA polymerases is responsible for the variation in plaque morphology and diversity in virulence. This can be a useful tool in characterizing mechanisms that facilitate virus adaptation and evolution. Keywords: RNA viruses; quasispecies; spontaneous mutations; virulence; plaque phenotype 1. Introduction With their diverse differences in size, structure, genome organization and replication strategies, RNA viruses are recognized as being highly mutatable [1].
    [Show full text]
  • Anti-Measles Virus Monoclonal Antibody, Clone DW2,DW5 (DMABT-H21849) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Anti-Measles virus Monoclonal antibody, Clone DW2,DW5 (DMABT-H21849) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview Mouse Anti-Measles Blend Monoclonal Antibody Specificity A blend of two monoclonal antibodies that recognize the measles hemagglutinin protein by indirect immunofluorescence. Target Measles virus Immunogen Hemagglutinin protein obtained from Chicago wild type strain of measles Isotype IgG1 Source/Host Mouse Species Reactivity Measles virus Clone DW2,DW5 Conjugate Unconjugated Applications IF, IHC-P Format Ascites Size 100 μl Preservative None Storage Maintain at -20 °C in convenient aliquots for up to 12 months. BACKGROUND Introduction Hemagglutinin (HA) is a class I viral fusion protein from Influenza virus. It is a major glycoprotein, comprising over 80% of the envelope proteins present in the virus particle. HA binds to sialic acid-containing receptors on the cell surface, bringing about the attachment of the virus particle to the cell, and is responsible for penetration of the virus into the cell cytoplasm by mediating the fusion of the membrane of the endocytosed virus particle with the endosomal membrane. The extent of infection into host organism is determined by HA. In natural infection, inactive HA is 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved matured intoIB2and HA2 outside the cell by one or more trypsin-like, arginine-specific endoproteases secreted by the bronchial epithelial cells. The HA protein is a homotrimer of disulfide-linked HA1-HA2.
    [Show full text]
  • Bioinformatic and Immunological Analysis Reveals Lack of Support For
    Polymeros et al. BMC Medicine 2014, 12:139 http://www.biomedcentral.com/1741-7015/12/139 RESEARCH ARTICLE Open Access Bioinformatic and immunological analysis reveals lack of support for measles virus related mimicry in Crohn’s disease Dimitrios Polymeros1, Zacharias P Tsiamoulos1*, Andreas L Koutsoumpas2, Daniel S Smyk2, Maria G Mytilinaiou2, Konstantinos Triantafyllou1, Dimitrios P Bogdanos2,3 and Spiros D Ladas4 Abstract Background: A link between measles virus and Crohn’s disease (CD) has been postulated. We assessed through bioinformatic and immunological approaches whether measles is implicated in CD induction, through molecular mimicry. Methods: The BLAST2p program was used to identify amino acid sequence similarities between five measles virus and 56 intestinal proteins. Antibody responses to measles/human mimics were tested by an in-house ELISA using serum samples from 50 patients with CD, 50 with ulcerative colitis (UC), and 38 matched healthy controls (HCs). Results: We identified 15 sets of significant (>70%) local amino acid homologies from two measles antigens, hemagglutinin-neuraminidase and fusion-glycoprotein, and ten human intestinal proteins. Reactivity to at least one measles 15-meric mimicking peptide was present in 27 out of 50 (54%) of patients with CD, 24 out of 50 (48%) with UC (CD versus UC, p = 0.68), and 13 out of 38 (34.2%) HCs (CD versus HC, p = 0.08). Double reactivity to at least one measles/human pair was present in four out of 50 (8%) patients with CD, three out of 50 (6%) with UC (p = 0.99), and in three out of 38 (7.9%) HCs (p >0.05 for all).
    [Show full text]
  • The Neonatal Anti-Viral Response Fails to Control Measles Virus Spread in Neurons Despite Interferon- Gamma Expression and a Th1-Like Cytokine Profile Priya Ganesan
    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 1-1-2017 The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon- gamma expression and a Th1-like cytokine profile Priya Ganesan Follow this and additional works at: https://dsc.duq.edu/etd Part of the Developmental Neuroscience Commons, Immunology and Infectious Disease Commons, and the Virology Commons Recommended Citation Ganesan, P. (2017). The neonatal anti-viral response fails to control measles virus spread in neurons despite interferon-gamma expression and a Th1-like cytokine profile (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/ 230 This One-year Embargo is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. THE NEONATAL ANTI-VIRAL RESPONSE FAILS TO CONTROL MEASLES VIRUS SPREAD IN NEURONS DESPITE INTERFERON-GAMMA EXPRESSION AND A TH1-LIKE CYTOKINE PROFILE A Dissertation Submitted to the Graduate School of Pharmaceutical Sciences Duquesne University In partial fulfillment of the requirements for the degree of Doctor of Philosophy By Priya Ganesan December 2017 Copyright by Priya Ganesan 2017 THE NEONATAL ANTI-VIRAL RESPONSE FAILS TO CONTROL MEASLES VIRUS SPREAD IN NEURONS DESPITE INTERFERON-GAMMA EXPRESSION AND A TH1-LIKE CYTOKINE PROFILE By Priya Ganesan Approved November 12, 2017 Lauren A. O’Donnell, Ph.D. Paula A. Witt-Enderby, Ph.D. Associate Professor of Pharmacology Professor of Pharmacology Graduate School of Pharmaceutical Sciences Graduate School of Pharmaceutical Sciences Duquesne University, Pittsburgh, PA Duquesne University, Pittsburgh, PA (Committee Chair) (Committee Member) Wilson S.
    [Show full text]
  • Molecular Requirements of Influenza Virus Hemagglutinin for Site-Specific
    Dissertation zur Erlangung des akademischen Grades d o c t o r r e r u m n a t u r a l i u m (Dr. rer. nat.) im Fach Biologie Eingereicht an der Lebenswissenschaftlichen Fakultät der Humboldt-Universität zu Berlin von Diplom-Biologin Katharina Brett Präsident der Humboldt-Universität zu Berlin Prof. Dr. Jan-Hendrik Olbertz Dekan der Lebenswissenschaftlichen Fakultät Prof. Dr. Richard Lucius Gutachter/Innen: 1. PD Dr. Michael Veit 2. Prof. Dr. Alexander Herrmann 3. Prof. Alexey Zaikin Tag der mündlichen Prüfung: 26.06.2015 Abbreviations ................................................................................................................................. i Zusammenfassung ........................................................................................................................ ii Summary ....................................................................................................................................... iii CHAPTER 1 – Introduction 1.1 Influenza Virus ........................................................................................................................1 1.1.1 Structure and composition of virus particles .............................................................2 1.1.2 Genetic variation between of influenza strains ..........................................................3 1.2 The Influenza spike protein Hemagglutinin 1.2.1 Molecular structure and biosynthesis .........................................................................4 1.2.2 Three-dimensional
    [Show full text]
  • Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer Evanthia Galanis1,2, Pamela J
    Published OnlineFirst November 14, 2014; DOI: 10.1158/0008-5472.CAN-14-2533 Cancer Clinical Studies Research Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer Evanthia Galanis1,2, Pamela J. Atherton3, Matthew J. Maurer3, Keith L. Knutson4,5, Sean C. Dowdy6, William A. Cliby6, Paul Haluska Jr1, Harry J. Long1, Ann Oberg3, Ileana Aderca2, Matthew S. Block1, Jamie Bakkum-Gamez6, Mark J. Federspiel2, Stephen J. Russell2, Kimberly R. Kalli1, Gary Keeney7, Kah Whye Peng2, and Lynn C. Hartmann1 Abstract Edmonstonvaccinestrainsofmeasles virus(MV)havesignificant other contemporary series. MV receptor CD46 and nectin-4 expres- antitumor activity in mouse xenograft models of ovarian cancer. sion was confirmed by immunohistochemistry in patient tumors. MV engineered to express the sodium iodide symporter gene (MV- Sodium iodide symporter expression in patient tumors after treat- NIS) facilitates localization of viral gene expression and offers a tool ment was confirmed in three patients by 123IuptakeonSPECT/CTs for tumor radiovirotherapy. Here, we report results from a clinical and was associated with long progression-free survival. Immune evaluation of MV-NIS in patients withtaxol- and platinum-resistant monitoring posttreatment showed an increase in effector T cells ovarian cancer. MV-NIS was given intraperitoneally every 4 weeks recognizing the tumor antigens IGFBP2 and FRa,indicatingthat for up to 6 cycles. Treatment was well tolerated and associated with MV-NIS treatment triggered cellular immunity against the patients' promising median overall survival in these patients with heavily tumor and suggesting that an immune mechanism mediating the pretreated ovarian cancer; no dose-limiting toxicity was observed in observed antitumor effect.
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 6,749,857 B1 Peters Et Al
    US006749857B1 (12) United States Patent (10) Patent N0.: US 6,749,857 B1 Peters et al. (45) Date of Patent: Jun. 15,2004 (54) RECOMBINANT DIMERIC ENVELOPE Primary Examiner—Laurie Scheiner VACCINE AGAINST FLAVIVIRAL Assistant Examiner—Jeffrey S. Parkin INFECTION (74) Attorney, Agent, or Firm—Morrison & Foerster LLP (75) Inventors: Iain D. Peters, BoZeman, MT (US); (57) ABSTRACT Beth-Ann G. Coller, WoluWe Saint Lambert (BE); Michael McDonell, The present invention discloses and claims vaccines Bogart, GA (US); John M. Ivy, College containing, as an active ingredient, a secreted recombinantly Station, TX (US); Kent Harada, produced dimeric form of truncated ?aviviral envelope Honolulu, HI (US) protein. The vaccines are capable of eliciting the production of neutralizing antibodies against ?aviviruses. The dimeric (73) Assignee: Hawaii Biotechnology Group, Inc., forms of truncated ?aviviral envelope protein are formed 1) Aiea, HI (US) by directly linking tWo tandem copies of 80% E in a head to ( * ) Notice: Subject to any disclaimer, the term of this tail fashion via a ?exible tether; 2) via the formation of a patent is extended or adjusted under 35 leucine Zipper domain through the homodimeric association U.S.C. 154(b) by 0 days. of tWo leucine Zipper helices each fused to the carboxy terminus of an 80% E molecule; or 3) via the formation of (21) Appl. No.: 09/376,463 a non-covalently associated four-helix bundle domain (22) Filed: Aug. 18, 1999 formed upon association of tWo helix-turn-helix moieties each attached to the carboxy terminus of an 80% E mol Related US. Application Data ecule.
    [Show full text]